Applied Genetic Technologies Corp. (NASDAQ:AGTC) – Roth Capital lifted their Q2 2017 earnings per share (EPS) estimates for Applied Genetic Technologies Corp. in a research report issued on Tuesday. Roth Capital analyst J. Pantginis now expects that the brokerage will post earnings per share of ($0.02) for the quarter, up from their prior forecast of ($0.55). Roth Capital currently has a “Buy” rating and a $15.00 target price on the stock. Roth Capital also issued estimates for Applied Genetic Technologies Corp.’s Q3 2017 earnings at ($0.14) EPS, Q4 2017 earnings at ($0.16) EPS, FY2017 earnings at ($0.12) EPS, FY2018 earnings at ($1.73) EPS, FY2019 earnings at ($2.27) EPS and FY2020 earnings at ($3.25) EPS.

Several other research analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Applied Genetic Technologies Corp. from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a report on Monday, October 17th. Wedbush reissued an “outperform” rating and set a $17.00 target price (down previously from $20.00) on shares of Applied Genetic Technologies Corp. in a report on Wednesday. BMO Capital Markets reduced their target price on shares of Applied Genetic Technologies Corp. from $25.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, September 13th. Janney Montgomery Scott raised shares of Applied Genetic Technologies Corp. from a “sell” rating to a “neutral” rating and set a $11.00 target price for the company in a report on Monday, September 26th. Finally, Wells Fargo & Co. cut shares of Applied Genetic Technologies Corp. from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Applied Genetic Technologies Corp. currently has an average rating of “Hold” and an average price target of $16.80.

Earnings History and Estimates for Applied Genetic Technologies Corp. (NASDAQ:AGTC)

Shares of Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 9.85 on Friday. The firm has a 50-day moving average of $8.58 and a 200 day moving average of $13.00. Applied Genetic Technologies Corp. has a 52 week low of $6.35 and a 52 week high of $21.43. The stock’s market cap is $177.82 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last announced its quarterly earnings results on Tuesday, November 8th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.28. The business had revenue of $11.80 million for the quarter, compared to analysts’ expectations of $10.21 million. Applied Genetic Technologies Corp. had a net margin of 23.63% and a return on equity of 10.56%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.53) EPS.

In related news, CFO Lawrence E. Bullock bought 10,000 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were acquired at an average price of $8.75 per share, for a total transaction of $87,500.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at $87,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mark S. Shearman bought 3,000 shares of the company’s stock in a transaction dated Thursday, September 22nd. The stock was bought at an average price of $8.87 per share, for a total transaction of $26,610.00. Following the transaction, the insider now owns 1,700 shares of the company’s stock, valued at $15,079. The disclosure for this purchase can be found here. 2.46% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in AGTC. Schroder Investment Management Group bought a new stake in shares of Applied Genetic Technologies Corp. during the second quarter valued at about $976,000. Emerald Acquisition Ltd. acquired a new position in Applied Genetic Technologies Corp. during the second quarter worth $1,782,000. DUPONT CAPITAL MANAGEMENT Corp acquired a new position in Applied Genetic Technologies Corp. during the second quarter worth $516,000. Acrospire Investment Management LLC raised its position in Applied Genetic Technologies Corp. by 13.1% in the second quarter. Acrospire Investment Management LLC now owns 15,943 shares of the company’s stock worth $225,000 after buying an additional 1,842 shares during the last quarter. Finally, Globeflex Capital L P acquired a new position in Applied Genetic Technologies Corp. during the second quarter worth $997,000. Institutional investors and hedge funds own 61.31% of the company’s stock.

About Applied Genetic Technologies Corp.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

5 Day Chart for NASDAQ:AGTC

Receive News & Stock Ratings for Applied Genetic Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp. and related stocks with our FREE daily email newsletter.